Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Matthew C Solhjem"'
Autor:
Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely, Amanda Hayman, David O'Brien, Rehan Ahmad, Jeffrey V Manchio, Nathaniel Fox, Kayla McCarty, Michaela Phillips, Evelyn Brosnan, Gina Vaccaro, Rui Li, Miklos Simon, Eric Bernstein, Mary McCormick, Lena Yamasaki, Yaping Wu, Ashley Drokin, Trevor Carnahan, Yy To, William L Redmond, Brian Lee, Jeannie Louie, Eric Hansen, Matthew C Solhjem, Julie Cramer, Walter J Urba, Michael J Gough, Marka R Crittenden, Kristina H Young
Publikováno v:
The Lancet. Oncology. 23(9)
TGF-β is an immunosuppressive cytokine that is upregulated in colorectal cancer. TGF-β blockade improved response to chemoradiotherapy in preclinical models of colorectal adenocarcinoma. We aimed to test the hypothesis that adding the TGF-β type I
Autor:
Benjamin Cottam, Kristina Young, Pippa Newell, Todd Crocenzi, Chet Hammill, Zeljka Jutric, Ronald F. Wolf, Paul D. Hansen, Matthew C. Solhjem, Yue-Yun To, Amy Greathouse, Garth Tormoen, Keith S. Bahjat, Michael J. Gough, Marka R. Crittenden
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Preclinical studies have shown synergy between radiation therapy and immunotherapy. However, in almost all preclinical models, radiation is delivered in single doses or short courses of high doses (hypofractionated radiation). By contrast
Externí odkaz:
https://doaj.org/article/2403eb5742d0484c8d84f42cda596a9b
Autor:
Nancy L. Bartlett, Christopher J. Schultz, John H. Suh, Matthew C. Solhjem, Maria Werner-Wasik, Jon Glass, Felix Bokstein, Barbara Fisher, Daniel J. Brat, Mark Augspurger, Joseph Bovi, Minhee Won, Minesh P. Mehta, Marcia K. Liepman
Publikováno v:
Journal of Clinical Oncology. 34:1620-1625
Purpose This study investigated the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and subsequent TMZ. The primary phase I end point was the maxim
Autor:
Matthew C. Solhjem, Pippa Newell, Ronald F. Wolf, Paul D. Hansen, Michael J. Gough, Kristina H. Young, Benjamin Cottam, Chet W. Hammill, Todd S. Crocenzi, Keith S. Bahjat, Zeljka Jutric, Marka R. Crittenden, Garth W. Tormoen, Amy Greathouse, Yue-Yun To
Publikováno v:
Journal for Immunotherapy of Cancer
Crocenzi, T; Cottam, B; Newell, P; Wolf, RF; Hansen, PD; Hammill, C; et al.(2016). A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 4, 45. doi: 10.1186/s40425-016-0149-6. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/4x4214z6
Crocenzi, T; Cottam, B; Newell, P; Wolf, RF; Hansen, PD; Hammill, C; et al.(2016). A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 4, 45. doi: 10.1186/s40425-016-0149-6. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/4x4214z6
Background Preclinical studies have shown synergy between radiation therapy and immunotherapy. However, in almost all preclinical models, radiation is delivered in single doses or short courses of high doses (hypofractionated radiation). By contrast
Autor:
Matthew C. Solhjem, Steven K. Seung
Publikováno v:
Journal of Cancer Therapy. :190-195
Purpose: Patients with locally recurrent lung cancer after definitive radiation therapy pose a challenge in management. Surgery is often not an option and chemotherapy offers poor long-term local control. Stereotactic body radiotherapy (SBRT) was inv
Autor:
Eric Hansen, Jeannie Louie, Matthew C. Solhjem, Steven K. Seung, Christine Cha, Stephen B. Bader, K. Underhill, David E. Gannett, Joseph Bae
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 72:1075-1081
Purpose To review outcomes with intensity-modulated radiation therapy (IMRT) in the community setting for the treatment of nasopharyngeal and oropharyngeal cancer. Methods and Materials Between April 2003 and April 2007, 69 patients with histological
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 62:1379-1384
Purpose To determine the efficacy and complications of adjuvant vaginal high-dose-rate brachytherapy alone for patients with Stage I endometrial cancer in whom complete surgical staging had been performed. Methods and Materials Between April 1998 and
Autor:
Michael G. Herman, Thomas M. Pisansky, Lance A. Mynderse, Bernard F. King, Matthew C. Solhjem, Torrence M. Wilson, Susan Geyer, Brian J. Davis
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 60:767-776
To quantify prostate volume (pvol) changes with transrectal ultrasound (TRUS) immediately after permanent prostate brachytherapy (PPB) and to correlate these changes with postimplant computed tomography (CT) volumetrics. To provide data relevant to e
Autor:
David W. Hillman, Brian J. Davis, Torrence M. Wilson, Matthew C. Solhjem, Lance A. Mynderse, Michael G. Herman, Bernard F. King, Thomas M. Pisansky
Publikováno v:
Cancer journal (Sudbury, Mass.). 10(6)
Purpose Limited duration neoadjuvant cytoreductive hormonal therapy (NHT) is used before the definitive radiotherapeutic management of prostate cancer to decrease target volume size and/or to decrease urinary obstructive symptoms. The purpose of this
Autor:
Steven K. Seung, Michael Owens, Ronald L. Wolf, Chet W. Hammill, Walter J. Urba, Anupama Kurup, Marka R. Crittenden, Lehel Somogyi, Michael J. Gough, James Regan, Todd S. Crocenzi, Matthew C. Solhjem, Carlo Bifulco, Michael Phillips, Shane Orion Rogosin, Pippa Newell, Alan Savoy, Xiaohong Cai, Alexandru Bageac
Publikováno v:
Journal of Clinical Oncology. 31:174-174
174 Background: The primary aim of this exploratory trial was to determine the feasibility and safety of chemoradiotherapy (CRT) with combinatorial immunotherapy in LA or BR PC. Methods: 10 patients (pts) with untreated, LA (n=6) or BR (n=4) biopsy-p